Clinical trials
Psilocybin clinical trials
Below are recruiting psilocybin clinical trials, each written for real people, not researchers. We’re tracking 100 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07063862RecruitingPhase 3
Psychedelic microdose for emotional distress in advanced illness
This trial tests whether very low doses of psilocybin (a psychedelic substance) can help reduce emotional distress in people with a life-limiting illness. If you are receiving palliative care and feeling anxious or depressed, this study might offer a way to explore a new treatment option.
Brampton, OntarioAges 18 years+ - NCT06814522RecruitingPhase 1/Phase 2
Study of psilocybin therapy for doctor burnout
This study tests whether psilocybin, given with professional therapy support, can help UCSD doctors who are feeling burned out. You would attend several clinic visits to receive the medicine and talk through your experiences.
San Diego, CaliforniaAges 21–70 - NCT06512194RecruitingPhase 2
Psilocybin for depression study
This trial tests whether psilocybin can help people with major depression who are currently having a depressive episode. It aims to understand how the treatment works and if it is safe and effective.
Edwards, ColoradoAges 18–70 - NCT06818994RecruitingPhase 1
Psilocybin therapy for low mood in advanced cancer
This trial tests if a medicine called psilocybin, given with talk therapy, can safely help people with advanced cancer who feel very demoralized. Demoralization is a deep sense of hopelessness or loss of meaning. The goal is to see if this treatment can improve your emotional well-being.
Kingston, OntarioAges 18–70 - NCT05570708Enrolling by invitation
Therapist training trial on how experience shapes therapy
This study looks at how therapists’ personal experience affects their attitude and skills during substance-assisted therapy training. It’s mainly for therapists-in-training, and may help improve how future training and therapy are delivered safely.
BaselAges 27 years+ - NCT05403086RecruitingPhase 2
Psilocybin for distress in people with serious, life-limiting illness
This Phase 2 study tests whether psilocybin therapy can reduce deep distress (“demoralization”) in people receiving palliative (comfort-focused) care. It may help with mood and well-being, but you must meet safety and medication requirements to join.
Greenbrae, CaliforniaAges 18 years+ - NCT06626139RecruitingPhase 2
Psilocybin study for healthy volunteers
This trial tests how the setting and context affect the experience of psilocybin, a psychedelic drug. It aims to understand how the environment influences the effects in healthy adults.
San Francisco, CaliforniaAges 21–70 - NCT06471959RecruitingPhase 1/Phase 2
Psychedelic group program for first responders with mental health issues
This study tests a group therapy program that includes a psychedelic medicine for first responders struggling with conditions like depression, anxiety, or PTSD. It is a 12-week program with mostly remote sessions and two in-person visits.
Surrey, British ColumbiaAges 19–65 - NCT06355414RecruitingPhase 1
Psilocybin for chronic back pain and depression
This trial tests if psilocybin, a psychedelic drug, can help people with long-term low back pain who also have depression. If you qualify, you'll receive psilocybin in a controlled setting, and researchers will see how it affects your pain and mood.
Baltimore, MarylandAges 21–80 - NCT05398484RecruitingPhase 2/Phase 3
Psilocybin therapy for advanced cancer-related anxiety
This trial studies whether psilocybin (with support and therapy) can reduce anxiety in people with advanced cancer. It may help with distress and quality of life, while the study team monitors safety closely.
Aurora, ColoradoAges 21–100 - NCT07281352RecruitingPhase 1/Phase 2
Psilocybin therapy for depression
This study tests if psilocybin (a psychedelic) combined with cognitive behavioral therapy (CBT) can help people with major depression. You would receive the psilocybin in a supervised setting and have talk therapy before and after.
Los Angeles, CaliforniaAges 21–60 - NCT06001749RecruitingPhase 2
Psilocybin for cancer pain study
This trial tests whether psilocybin (a psychedelic drug) can help with severe cancer pain. You may qualify if your pain is high despite strong medications and you are willing to be monitored closely.
Boston, MassachusettsAges 18 years+ - NCT07118332RecruitingEarly Phase 1
Psilocybin for chronic pain in veterans who smoke
This trial tests if psilocybin can help veterans with chronic pain who also smoke cigarettes. You will take psilocybin in a controlled setting to see if it reduces pain and helps with smoking.
West Haven, ConnecticutAges 21–65 - NCT07737054RecruitingEarly Phase 1
Psilocybin therapy for PTSD
This trial tests a type of therapy that uses psilocybin (a safe, natural substance found in certain mushrooms) to help people with PTSD. It combines talk therapy with the medicine to see if it can reduce trauma symptoms.
Tel AvivAges 21–65 - NCT06518720RecruitingPhase 2
Psilocybin for Chronic Nerve Pain and Depression
This trial tests whether psilocybin (a psychedelic medication) can help people who have both chronic nerve pain and depression that hasn't responded to standard treatments. The goal is to see if it can reduce pain and improve mood.
Toronto, OntarioAges 18–65 - NCT06706232RecruitingPhase 2
Psilocybin for Depression and Suicidal Thoughts in Bipolar II
This trial tests if two doses of psilocybin, given under medical supervision, are safe and acceptable for people with Bipolar II disorder who have mild to moderate depression and certain suicidal thoughts. The goal is to see if it may help improve mood and reduce suicidal thinking.
Houston, TexasAges 25–70 - NCT07732166RecruitingEarly Phase 1
Psilocybin and Self-Awareness Study
This trial tests whether a single dose of psilocybin (a psychedelic substance) can change self-awareness in healthy adults. It aims to understand how this substance affects the brain, which might lead to new mental health treatments.
Rio de Janeiro, Rio de JaneiroAges 21–60 - NCT05301608RecruitingPhase 1/Phase 2
Psilocybin study of brain activity and changing thoughts
This Phase 1/2 study tests psilocybin to see how it affects brain signals and the “content” of thoughts while you are monitored during the study. Because participants must be generally healthy and mentally stable, it may be an option if you meet those safety and medication rules and are comfortable having your brain activity measured.
Baltimore, MarylandAges 18–75 - NCT07610369RecruitingPhase 2
Psilocybin therapy for depression in Parkinson's disease
This study tests whether psilocybin (a psychedelic compound) combined with therapy can reduce depression in people with Parkinson's disease. If you have moderate-to-severe depression and Parkinson's, this trial may offer a new treatment option.
New Haven, ConnecticutAges 40–80 - NCT06067737RecruitingPhase 2
Psilocybin and buprenorphine for opioid use disorder
This study tests whether adding psilocybin (a psychedelic medicine) to buprenorphine (a medication for opioid use disorder) can help people stop using opioids and stay in recovery. It is for people who have already been on buprenorphine but are still using other opioids.
Baltimore, MarylandAges 21–70 - NCT06247839RecruitingPhase 3
Psilocybin for depression: changing self-focus
This trial tests whether a single dose of psilocybin can help people with treatment-resistant depression by changing how they focus on themselves. It aims to understand how psilocybin affects brain activity and self-related thinking.
Charlestown, MassachusettsAges 18–55 - NCT07703722RecruitingPhase 3
Psilocybin and therapy for depression with trauma
This trial tests psilocybin (a compound from certain mushrooms) combined with a structured therapy to see if it helps people with depression linked to trauma. It focuses on how the treatment affects the connection between the gut and brain.
Islamabad, CapitalAges 18–60 - NCT04123314RecruitingEarly Phase 1
Psilocybin study for depression in mild memory or early Alzheimer’s
This early-phase study tests whether psilocybin (a psychedelic substance) can help with depression in people who have mild memory problems or early Alzheimer’s. The trial also closely monitors safety, thinking changes, mood, and blood pressure before and after dosing.
Baltimore, MarylandAges 18–85 - NCT04882839RecruitingPhase 2
Therapy with psilocybin for severe OCD symptoms
This Phase 2 study tests whether psilocybin-assisted psychotherapy can reduce symptoms in adults with severe, treatment-resistant OCD. It also focuses on safety and whether this approach is practical to run.
BeershebaAges 18–65
Hear when a new Psilocybin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psilocybin?
- Yes. Clin2 currently lists 100 recruiting psilocybin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psilocybin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psilocybin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.